Revisiting the cost-effectiveness of the COMBINE study for alcohol dependent patients: the patient perspective
- PMID: 20355261
- PMCID: PMC3140763
- DOI: 10.1097/mlr.0b013e3181ca3d40
Revisiting the cost-effectiveness of the COMBINE study for alcohol dependent patients: the patient perspective
Abstract
Objective: Most cost and cost-effectiveness studies of substance abuse treatments focus on the costs to the provider/payer. Although this perspective is important, the costs incurred by patients should also be considered when evaluating treatment. This article presents estimates of patients' costs associated with the Combined Pharmacotherapies and Behavioral Interventions (COMBINE) alcohol treatments and evaluates the treatments' cost-effectiveness from the patient perspective.
Study design: A prospective cost-effectiveness study of patients in COMBINE, a randomized controlled clinical trial of 9 alternative alcohol treatment regimens involving 1383 patients with diagnoses of primary alcohol dependence across 11 US clinic sites. We followed a microcosting approach that allowed estimation of patients' costs for specific COMBINE treatment activities. The primary clinical outcomes from COMBINE are used as indicators of treatment effectiveness.
Results: The average total patient time devoted to treatment ranged from about 30 hours to 46 hours. Time spent traveling to and from treatment sessions and participation in self-help meetings accounted for the largest portion of patient time costs. The cost-effectiveness results indicate that 6 of the 9 treatments were economically dominated and only 3 treatments are potentially cost-effective depending on patient's willingness to pay for the considered outcomes: medical management (MM) + placebo, MM + naltrexone, and MM + naltrexone + acamprosate.
Conclusions: Few studies consider the patient's perspective in estimating costs and cost-effectiveness even though these costs may have a substantial impact on a patient's treatment choice, ability to access treatment, or treatment adherence. For this study, the choice of the most cost-effective treatment depends on the value placed on the outcomes by the patient, and the conclusions drawn by the patient may differ from that of the provider/payer.
Similar articles
-
Cost and cost-effectiveness of the COMBINE study in alcohol-dependent patients.Arch Gen Psychiatry. 2008 Oct;65(10):1214-21. doi: 10.1001/archpsyc.65.10.1214. Arch Gen Psychiatry. 2008. PMID: 18838638 Free PMC article. Clinical Trial.
-
The effect of alcohol treatment on social costs of alcohol dependence: results from the COMBINE study.Med Care. 2010 May;48(5):396-401. doi: 10.1097/MLR.0b013e3181d68859. Med Care. 2010. PMID: 20393362 Free PMC article.
-
Measuring economic outcomes of alcohol treatment using the Economic Form 90.J Stud Alcohol Drugs. 2007 Mar;68(2):248-55. doi: 10.15288/jsad.2007.68.248. J Stud Alcohol Drugs. 2007. PMID: 17286343 Clinical Trial.
-
New pharmacotherapies for alcohol dependence.Med J Aust. 2002 Jul 15;177(2):103-7. doi: 10.5694/j.1326-5377.2002.tb04683.x. Med J Aust. 2002. PMID: 12098353 Review.
-
A pharmaceutical industry perspective on the economics of treatments for alcohol and opioid use disorders.Ann N Y Acad Sci. 2014 Oct;1327(1):112-30. doi: 10.1111/nyas.12538. Epub 2014 Sep 18. Ann N Y Acad Sci. 2014. PMID: 25236185 Free PMC article. Review.
Cited by
-
Economic evaluations of alcohol pharmacotherapy: Systematic review of economic evaluations of pharmacotherapy for the treatment of alcohol use disorder.Aust N Z J Psychiatry. 2024 Feb;58(2):117-133. doi: 10.1177/00048674231201541. Epub 2023 Oct 12. Aust N Z J Psychiatry. 2024. PMID: 37822267 Free PMC article. Review.
-
Cost-effectiveness of alcohol use treatments in patients with alcohol-related cirrhosis.J Hepatol. 2021 Jun;74(6):1286-1294. doi: 10.1016/j.jhep.2020.12.004. Epub 2020 Dec 14. J Hepatol. 2021. PMID: 33326815 Free PMC article.
-
Estimating Long-Term Drinking Patterns for People with Lifetime Alcohol Use Disorder.Med Decis Making. 2019 Oct;39(7):765-780. doi: 10.1177/0272989X19873627. Epub 2019 Oct 3. Med Decis Making. 2019. PMID: 31580211 Free PMC article.
-
Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: a systematic review and meta-analysis.BMC Med. 2019 Jan 15;17(1):10. doi: 10.1186/s12916-018-1242-0. BMC Med. 2019. PMID: 30642329 Free PMC article.
-
Systematic Review of Combined Pharmacotherapy for the Treatment of Alcohol Use Disorder in Patients Without Comorbid Conditions.CNS Drugs. 2018 Jan;32(1):13-31. doi: 10.1007/s40263-017-0484-2. CNS Drugs. 2018. PMID: 29273901
References
-
- Tucker JA, Vuchinich RE, Rippens PD. A factor analytic study of influences on patterns of help-seeking among treated and untreated alcohol dependent persons. J Subst Abuse Treat. 2004;26:237–242. - PubMed
-
- Weisner C, Matzger H, Tam T, et al. Who goes to alcohol and drug treatment? Understanding utilization within the context of insurance. J Stud Alcohol. 2002;63:673–682. - PubMed
-
- Hasin DS, Grant BF. AA and other helpseeking for alcohol problems: former drinkers in the U.S. general population. J Subst Abuse Treat. 1995;7:281–292. - PubMed
-
- Hser Y, Maglione M, Polinsky ML, et al. Predicting drug treatment entry among treatment-seeking individuals. J Subst Abuse Treat. 1998;15(3):213–220. - PubMed
-
- Yarbroff KR, Warren JL, Knopf K, et al. Estimating patient time costs associated with colorectal cancer care. Med Care. 2005;43(7):640–648. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
